364 related articles for article (PubMed ID: 17989653)
1. New law broadens FDA safety authority, renews user fees.
Fox JL
Nat Biotechnol; 2007 Nov; 25(11):1189-90. PubMed ID: 17989653
[No Abstract] [Full Text] [Related]
2. FDA user fees and innovation.
Somberg J
Am J Ther; 2008; 15(2):97. PubMed ID: 18356626
[No Abstract] [Full Text] [Related]
3. FDA user fees approved.
Clin Pharm; 1993 Jan; 12(1):3. PubMed ID: 8428431
[No Abstract] [Full Text] [Related]
4. User fees to hasten FDA review.
Gershon D
Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
[No Abstract] [Full Text] [Related]
5. Pharmaceuticals and medical devices: FDA oversight.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
[No Abstract] [Full Text] [Related]
6. FDA user fee law poised for passage in Congress but not without stirring up controversy.
Finkelstein J
J Natl Cancer Inst; 2007 Jul; 99(14):1072-3. PubMed ID: 17623792
[No Abstract] [Full Text] [Related]
7. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-18. PubMed ID: 18345557
[No Abstract] [Full Text] [Related]
8. New drug law to speed scientific review.
Nature; 1992 Oct; 359(6396):563. PubMed ID: 1406977
[TBL] [Abstract][Full Text] [Related]
9. User-fee boost would up safety, reputations. A new paper suggests that drug makers, FDA can't afford not to raise user fees.
Med Health; 2005 Oct; 59(39):2, 4. PubMed ID: 16279192
[No Abstract] [Full Text] [Related]
10. Frustrated by regulatory delays at FDA, biotech companies warm to user fees.
Gershon D
Nature; 1992 Aug; 358(6388):616. PubMed ID: 1495553
[No Abstract] [Full Text] [Related]
11. FDA user fee and Modernisation Act.
Donawa M
Med Device Technol; 2002 Dec; 13(10):27-9. PubMed ID: 12575526
[TBL] [Abstract][Full Text] [Related]
12. Repeal law that puts "FDA on the payroll of the industry," says former NEJM editor.
Kmietowicz Z
BMJ; 2007 Mar; 334(7591):447. PubMed ID: 17332569
[No Abstract] [Full Text] [Related]
13. FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act.
Lee R
J Law Med Ethics; 2006; 34(1):131-4. PubMed ID: 16489994
[No Abstract] [Full Text] [Related]
14. FDA law enforcement: critical to product safety.
Rados C
FDA Consum; 2006; 40(1):21-7. PubMed ID: 16528823
[No Abstract] [Full Text] [Related]
15. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
DerGurahian J
Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
[No Abstract] [Full Text] [Related]
16. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
Lee VH
Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
[No Abstract] [Full Text] [Related]
17. ISO 9000. Policy implications for FDA. Taking the pulse of increasing global use of the ISO series of uniform quality standards by FDA regulated industries.
Schwemer WL; Lynch MA
J Parenter Sci Technol; 1993; 47(3):101-18. PubMed ID: 8360802
[No Abstract] [Full Text] [Related]
18. The risk we bear: the effects of review speed and industry user fees on new drug safety.
Olson MK
J Health Econ; 2008 Mar; 27(2):175-200. PubMed ID: 18207263
[TBL] [Abstract][Full Text] [Related]
19. Drug safety special: chasing shadows.
Frantz S
Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
[No Abstract] [Full Text] [Related]
20. The FDA Export Reform and Enhancement Act of 1996: the FDA's new extraterritorial authority over labeling and promotional practices.
Helmanis AM
Food Drug Law J; 1996; 51(4):631-5. PubMed ID: 11797732
[No Abstract] [Full Text] [Related]
[Next] [New Search]
